A Case-Based Exploration of CAR T-Cell Therapy for Multiple Myeloma — Where We Are, Where We’re Going

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

Module 1: Current Use of BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

• Structural makeup and manufacturing processes of available BCMA-directed CAR T-cell platforms
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated MM
• Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; overall survival (OS) findings with cilta-cel in CARTITUDE-4
• Identification of appropriate candidates for ide-cel and cilta-cel and optimal sequencing of those therapies in the context of other evidence-based approaches
• Ongoing studies, such as CARTITUDE-5, CARTITUDE-6, aMMbition and CARTITUDE-10, evaluating BCMA-targeted CAR T-cell therapies after induction therapy for MM

Module 2: Tolerability Considerations with BCMA-Targeted CAR T-Cell Therapy

• Comparative frequency and severity of cytokine release syndrome (CRS), neurologic toxicities and other acute adverse events (AEs) with available anti-BCMA CAR T-cell therapies
• Guideline-endorsed approaches for mitigation, monitoring and management of CRS; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum and signs and symptoms of neurologic toxicities documented with BCMA-targeted CAR T-cell therapy; appropriate monitoring and management
• Recommended algorithms for monitoring for, mitigating and managing other common (eg, cytopenias, hypogammaglobulinemia, infections) and potentially serious (eg, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, immune effector cell-associated enterocolitis) AEs documented with one or more anti-BCMA CAR T-cell platforms
• Rationale for and implications of the recent elimination of the REMS (Risk Evaluation and Mitigation Strategy) requirement for CAR T-cell therapy
• Incidence and severity of long-term toxicities associated with CAR T-cell therapies; optimal approaches to monitoring and management over time

Module 3: Other Novel Anti-BCMA CAR T-Cell Platforms Undergoing Investigation in MM

• Structural and mechanistic similarities and differences between the novel anti-BCMA CAR T-cell platform anitocabtagene autoleucel (anito-cel) and currently available constructs; implications for efficacy and tolerability
• Key efficacy and safety results from the registrational Phase II iMMagine-1 trial of anito-cel for relapsed/refractory (R/R) MM
• Tolerability profile of anito-cel relative to other BCMA-targeted CAR T-cell therapies
• FDA acceptance of a biologics license application for anito-cel as fourth- or later-line treatment for MM; potential clinical role and ongoing evaluation in earlier lines of therapy in the Phase III iMMagine-3 study
• Mechanism of action and manufacturing process of the BCMA/CD19 dual-targeting FasTCAR-T therapy AZD0120
• Preliminary efficacy and safety results from the Phase Ib/II DURGA-1 study of AZD0120 for R/R MM and from Phase I studies for newly diagnosed disease; future development plans

Module 4: Future Role of GPRC5D-Targeted CAR T-Cell Therapy in the Management of MM

• Biological rationale for the development of CAR T-cell platforms targeting GPRC5D in MM
• Response rates and other efficacy outcomes documented with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel (arlo-cel) for heavily pretreated MM in early-phase clinical trials
• Similarities and differences in tolerability among arlo-cel, available BCMA-targeted CAR T-cell therapies and GPRC5D-targeted bispecific antibodies
• FDA regenerative medicine advanced therapy designation for arlo-cel for R/R MM
• Positive top-line results from the registrational Phase II QUINTESSENTIAL trial and ongoing research, such as the Phase III QUINTESSENTIAL-2 trial, attempting to define the optimal clinical role of arlo-cel
• Early data with and ongoing investigation of other GPRC5D-targeted CAR T-cell constructs and platforms with other targets or unique manufacturing processes

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand the mechanism of action of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for patients with MM, and appreciate the similarities and differences among currently available and investigational agents in this class.
• Develop an understanding of the current clinical research database with FDA-approved BCMA-directed CAR T-cell therapy platforms in the management of relapsed/refractory MM in order to optimally integrate this novel therapeutic strategy into treatment algorithms.
• Appreciate the scientific justification for the development of next-generation BCMA-directed CAR T-cell approaches, and appraise available research findings with and ongoing efforts attempting to definitively establish the efficacy and safety of these agents.
• Review the biological rationale for and published and emerging research findings with CAR T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D) for MM, and evaluate the potential role of this therapeutic strategy.
• Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with CAR T-cell therapy for MM, and develop strategies to optimally identify and manage these side effects.
• Recognize the spectrum, frequency and severity of other adverse events, such as secondary hematologic malignancies, infections and cytopenias, associated with CAR T-cell therapy used in the care of patients with MM, and consider recommended approaches to prevent, ameliorate and manage these toxicities.
• Recall available data with novel CAR T-cell therapy-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Larson — Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Kite, A Gilead Company, Pfizer Inc, Regeneron Pharmaceuticals Inc; Speakers Bureaus: Regeneron Pharmaceuticals Inc; Stock OPTIONS — Private Companies: TORL BioTherapeutics (founders’ shares). Dr Martin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, GSK, Legend Biotech, Pfizer Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Sanofi; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Lilly. Dr Richard — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Legend Biotech; Consulting Agreements: Bristol Myers Squibb, Karyopharm Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, C4 Therapeutics, Heidelberg Pharma AG, Johnson & Johnson.

MODERATOR
Dr Voorhees — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CellCentric, GSK, Johnson & Johnson, Kite, A Gilead Company, Legend Biotech, Predicta Biosciences, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, GSK, Johnson & Johnson, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Karyopharm Therapeutics; Nonrelevant Financial Relationships: Multiple Myeloma Research Foundation.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, and Legend Biotech.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.